Abeona Therapeutics Inc (ABEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company focusing on the development and delivery of gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs include ABO-101 and ABO-102 adeno-associated virus. Abeona is also developing EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 for rare blood diseases. The company has partnership with AMAG Pharmaceuticals for the commercialization of its products in the US, Norgine B.V in European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia and New Zealand; RHEI Pharmaceuticals N.V in China; and Hanmi in South Korea. Abeona is headquartered in Dallas, Texas, the US.
Abeona Therapeutics Inc (ABEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company focusing on the development and delivery of gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs include ABO-101 and ABO-102 adeno-associated virus. Abeona is also developing EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 for rare blood diseases. The company has partnership with AMAG Pharmaceuticals for the commercialization of its products in the US, Norgine B.V in European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia and New Zealand; RHEI Pharmaceuticals N.V in China; and Hanmi in South Korea. Abeona is headquartered in Dallas, Texas, the US.
Abeona Therapeutics Inc (ABEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
2
List of Tables 4
List of Figures 5
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Abeona Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 14
Access Pharma Enters Into Agreement With Pharma Company 14
Licensing Agreements 15
PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 15
PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 16
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 17
Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 18
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 19
Access Pharma Enters into Licensing Agreement with Plasma Technologies 20
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
Equity Offering 23
Abeona Therapeutics to Raise up to USD75 Million in Public Offering of Shares 23
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 24
Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 25
PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 26
PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 27
PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 28
Access Pharma Completes Private Placement Of Units For US$4.7 Million 29
Access Pharma Files Registration Statement For Public Offering Of Units 30
Access Pharma Completes Private Placement Of Units For US$5.4 Million 31
Acquisition 32
PlasmaTech Biopharma Acquires Abeona Therapeutics 32
Abeona Therapeutics Inc - Key Competitors 34
Key Employees 35
Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 37
Mar 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights 39
Nov 10, 2016: Abeona Therapeutics Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights 41
Aug 16, 2016: Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights 42
May 16, 2016: Abeona Therapeutics Announces First Quarter 2016 Summary Financial Results and Recent Operational Highlights 43
Mar 08, 2016: Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights 44
Legal and Regulatory 46
Feb 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit 46
Product News 47
Oct 20, 2016: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK 47
Oct 14, 2016: Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK 49
Oct 05, 2016: Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A 50
Sep 08, 2016: Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa 51
Aug 04, 2016: Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA) 52
Aug 02, 2016: Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals 53
May 23, 2016: Abeona Therapeutics to Present at UBS 2016 Global Healthcare Conference 54
Apr 15, 2016: Abeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting 55
Feb 24, 2016: Abeona Therapeutics to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress 56
Product Approvals 57
Oct 25, 2016: Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A 57
Oct 18, 2016: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A 59
Feb 29, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase I/II Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) 60
Jan 11, 2016: Abeona Therapeutics Announces European Regulatory Approval for ABO-102 for patients with Sanfilippo syndrome 61
Jan 11, 2016: Abeona Therapeutics Announces Initial European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome 62
Clinical Trials 63
Nov 02, 2016: Abeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa 63
Sep 26, 2016: Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa 64
Sep 15, 2016: Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of MPS IIIA Gene Therapy 65
Mar 02, 2016: Abeona Therapeutics Highlights New Preclinical Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) Data at WORLDSymposium 2016 66
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
List Of Tables
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Abeona Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Abeona Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 14
Access Pharma Enters Into Agreement With Pharma Company 14
PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 15
PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 16
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 17
Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 18
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 19
Access Pharma Enters into Licensing Agreement with Plasma Technologies 20
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
Abeona Therapeutics to Raise up to USD75 Million in Public Offering of Shares 23
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 24
Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 25
PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 26
PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 27
PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 28
Access Pharma Completes Private Placement Of Units For US$4.7 Million 29
Access Pharma Files Registration Statement For Public Offering Of Units 30
Access Pharma Completes Private Placement Of Units For US$5.4 Million 31
PlasmaTech Biopharma Acquires Abeona Therapeutics 32
Abeona Therapeutics Inc, Key Competitors 34
Abeona Therapeutics Inc, Key Employees 35
Abeona Therapeutics Inc, Subsidiaries 36
List Of Figures
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Abeona Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
RELATED REPORTS
Abeona Therapeutics Inc (ABEO) - Financial and Strategic SWOT Analysis Review
Abeona Therapeutics Inc (ABEO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by
View ReportAbeona Therapeutics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Abeona Therapeutics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Abeona Therapeutics Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,
View ReportAnika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2021 Update
Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical and veterinary applications. Its major
View ReportChinook Therapeutics Inc (KDNY) - Financial and Strategic SWOT Analysis Review
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
